References
1. Ørstavik R, Gustavson K, Rohrer-Baumgartner N, et al. ADHD i
Norge: En statusrapport .https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2017/adhd_i_norge.pdf.
Accessed June 1, 2022
2. Helsedirektoratet. ADHD: Nasjonal faglig retningslinje.https://www.helsedirektoratet.no/retningslinjer/adhd.
Accessed June 1, 2022
3. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder.Lancet . Jul 16-22 2005;366(9481):237-48.
doi:10.1016/S0140-6736(05)66915-2
4. Caye A, Rocha TB, Anselmi L, et al. Attention-Deficit/Hyperactivity
Disorder Trajectories From Childhood to Young Adulthood: Evidence From a
Birth Cohort Supporting a Late-Onset Syndrome. JAMA Psychiatry .
Jul 1 2016;73(7):705-12. doi:10.1001/jamapsychiatry.2016.0383
5. Yu G, Li GF, Markowitz JS. Atomoxetine: A Review of Its
Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.J Child Adolesc Psychopharmacol . May 2016;26(4):314-26.
doi:10.1089/cap.2015.0137
6. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases
extracellular levels of norepinephrine and dopamine in prefrontal cortex
of rat: a potential mechanism for efficacy in attention
deficit/hyperactivity disorder. Neuropsychopharmacology . Nov
2002;27(5):699-711. doi:10.1016/S0893-133X(02)00346-9
7. Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular Effects
of Stimulant and Non-Stimulant Medication for Children and Adolescents
with ADHD: A Systematic Review and Meta-Analysis of Trials of
Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs . Mar
2017;31(3):199-215. doi:10.1007/s40263-017-0410-7
8. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of
atomoxetine. Clin Pharmacokinet . 2005;44(6):571-90.
doi:10.2165/00003088-200544060-00002
9. Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW,
Buitelaar JK. CYP2D6 metabolizer status and atomoxetine dosing in
children and adolescents with ADHD. Eur Neuropsychopharmacol . Feb
2008;18(2):79-86. doi:10.1016/j.euroneuro.2007.06.002
10. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose
and steady-state pharmacokinetics of tomoxetine in normal subjects.J Clin Pharmacol . May-Jun 1985;25(4):296-301.
doi:10.1002/j.1552-4604.1985.tb02842.x
11. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in
children and adolescents with attention deficit hyperactivity disorder.J Child Adolesc Psychopharmacol . Spring 2003;13(1):53-63.
doi:10.1089/104454603321666199
12. Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics
Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6
Genotype and Atomoxetine Therapy. Clin Pharmacol Ther . Jul
2019;106(1):94-102. doi:10.1002/cpt.1409
13. Choi CI, Bae JW, Lee YJ, Lee HI, Jang CG, Lee SY. Effects of CYP2C19
genetic polymorphisms on atomoxetine pharmacokinetics. J Clin
Psychopharmacol . Feb 2014;34(1):139-42.
doi:10.1097/JCP.0b013e3182a608a2
14. Frost J, Bernard JP, Dietrichs ES, et al. Tidsskr Nor
Laegeforen . Sep 24 2019;139(13)Nye anbefalinger ved
serumkonsentrasjonsmalinger av sentralstimulerende legemidler.
doi:10.4045/tidsskr.19.0385
15. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the
ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in
psychiatric patients. Clin Pharmacol Ther . Feb 2008;83(2):322-7.
doi:10.1038/sj.clpt.6100291
16. Waade RB, Hermann M, Moe HL, Molden E. Impact of age on serum
concentrations of venlafaxine and escitalopram in different CYP2D6 and
CYP2C19 genotype subgroups. Eur J Clin Pharmacol . Aug
2014;70(8):933-40. doi:10.1007/s00228-014-1696-8
17. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6
Genotype to Phenotype Translation: Consensus Recommendations from the
Clinical Pharmacogenetics Implementation Consortium and Dutch
Pharmacogenetics Working Group. Clin Transl Sci . Jan
2020;13(1):116-124. doi:10.1111/cts.12692
18. Matsui A, Azuma J, Witcher JW, et al. Pharmacokinetics, safety, and
tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in
healthy Japanese men. J Clin Pharmacol . Mar 2012;52(3):388-403.
doi:10.1177/0091270011398657
19. de Leon J. Translating Pharmacogenetics to Clinical Practice: Do
Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine
Doses? J Am Acad Child Adolesc Psychiatry . Jul 2015;54(7):532-4.
doi:10.1016/j.jaac.2015.04.003
20. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J.
CYP2D6 and clinical response to atomoxetine in children and adolescents
with ADHD. J Am Acad Child Adolesc Psychiatry . Feb
2007;46(2):242-51. doi:10.1097/01.chi.0000246056.83791.b6
21. Fijal BA, Guo Y, Li SG, et al. CYP2D6 predicted metabolizer status
and safety in adult patients with attention-deficit hyperactivity
disorder participating in a large placebo-controlled atomoxetine
maintenance of response clinical trial. J Clin Pharmacol . Oct
2015;55(10):1167-74. doi:10.1002/jcph.530
Tables
Table 1. Demographics of the study population.